On January 13, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas (Press release, MaaT Pharma, JAN 13, 2022, View Source [SID1234605458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With a research report named "Échec et MaaT pour le cancer", Portzamparc / Groupe BNP Paribas today initiates coverage of MaaT Pharma with a Buy recommendation.

This coverage of MaaT Pharma stock comes in addition to the ones initiated in December 2021 by brokerage firms KBC Securities with a Buy recommendation (research report "More than a Gut Feeling") and Kempen, also with a Buy recommendation (research report "No Guts no Glory").

Next financial communication:

February 28th, 2022, after stock market closes: publication of the 2021 revenues and cash position as of December 31st, 2021.